GSK rolls out new Alli ads, study

Share this article:
GSK rolls out new Alli ads, study
GSK rolls out new Alli ads, study
GlaxoSmithKline has revamped advertising for its OTC weight loss drug Alli to emphasize bad eating habits.

TV, print and online ads bearing the tagline “Eat Healthier, Live Happier” debuted in January, targeting women concerned about their weight. Elements of the consumer campaign are also being used in retail and promotions to healthcare professionals.

The campaign is the last work for the brand by Arnold, which lost the account to TBWA shortly after wrapping up work on it. New ads from TBWA will debut later this year.

The new ads coincide with the release of a survey exploring “America's unhealthy relationship with food.” The survey found a disconnect between Americans' perceptions of their eating habits – 74% said they have a healthy relationship with food – and the fact that, by some estimates, two-thirds of Americans are overweight or obese.

“Our study showed that many Americans are engaging in mindless or emotional eating habits,” said GSK VP, Alli Rachel Ferdinando in a statement. “That is, eating without thinking about nutritional value or portion size, or eating in response to feelings instead of to hunger. These unhealthy habits can lead to weight gain and are contributing to our burgeoning obesity crisis. It's time we look at our relationship with food through this lens so people can begin to understand why they overeat and learn healthier habits for life.”

Edelman is handling PR on the study, which the company may incorporate into professional outreach.

GSK is also sponsoring a documentary film about eating, in partnership with the Creative Coalition. The company agreed to a hands-off role in the film's production, with full creative control in the hands of the non-profit Creative Coalition and the director and no guarantee that Alli will be mentioned. The GSK eating study will be the subject of a panel discussion featuring celebs at this month's Sundance film fest.

Alli launched in 2007 with a $150 million ad campaign and took lumps from analysts as sales slumped in 2008. At launch, GSK projected the brand could reach $1.5 billion in sales. Third-quarter global sales were around $80 million.
Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

MM&M Future Leaders

Register now

Early bird $1,950 before 31 October 2014

*Group discounts available on request 


Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...